NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Paving the Way for NDA Submission
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative disorders, including Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently achieved a significant milestone in its drug development process. In early October, the company held a meeting with the U.S. Food and Drug Administration (“FDA”), where it received clearance to proceed with pivotal Phase 3 studies for its lead compound, buntanetap. “We are now ready to move into the highly anticipated Phase 3 stage,” Maria Maccecchini, Ph.D., founder, president and CEO of Annovis Bio, was quoted as saying. “Our priority is to bring…







